Werewolf Therapeutics (HOWL) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US95075A1079
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is a biopharmaceutical company based in Watertown, Massachusetts. They focus on developing innovative therapeutics that harness the body's immune system to combat cancer.
The company utilizes its exclusive PREDATOR platform to create molecules that can activate the immune response in a targeted way, overcoming challenges commonly seen with traditional immune therapies.
Werewolf Therapeutics' key products include WTX-124 and WTX-330, both Interleukin-based molecules currently in Phase I clinical trials. These molecules aim to treat advanced solid tumors and lymphoma by activating specific immune pathways.
In addition to their lead products, Werewolf Therapeutics is also working on JZP898 and WTX-712, molecules that target interferon alpha and IL-21 respectively, to further expand their cancer treatment portfolio.
Founded in 2017, Werewolf Therapeutics continues to advance its cutting-edge approach to cancer therapy and improve patient outcomes. To learn more about their work, visit their website at https://werewolftx.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
HOWL Stock Overview
| Market Cap in USD | 201m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2021-04-30 |
HOWL Stock Ratings
| Growth 5y | -3.08 |
| Fundamental | -47.8 |
| Dividend | - |
| Rel. Performance vs Sector | 9.52 |
| Analysts | 4.60/5 |
| Fair Price Momentum | 7.45 USD |
| Fair Price DCF | - |
HOWL Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
HOWL Growth Ratios
| Growth 12m | 163.14% |
| Growth Correlation 12m | 34% |
| Growth Correlation 3m | -17% |
| CAGR 5y | -27.24% |
| Sharpe Ratio 12m | 1.41 |
| Alpha vs SP500 12m | 134.16 |
| Beta vs SP500 5y weekly | 1.27 |
| ValueRay RSI | 72.19 |
| Volatility GJR Garch 1y | 92.12% |
| Price / SMA 50 | -0.64% |
| Price / SMA 200 | 59.23% |
| Current Volume | 78.7k |
| Average Volume 20d | 196.4k |
External Links for HOWL Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 26, 2024, the stock is trading at USD 6.21 with a total of 78,714 shares traded.
Over the past week, the price has changed by +5.79%, over one month by +3.33%, over three months by +46.81% and over the past year by +165.38%.
According to ValueRays Forecast Model, HOWL Werewolf Therapeutics will be worth about 8.3 in April 2025. The stock is currently trading at 6.21. This means that the stock has a potential upside of +34.3%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 12.5 | 101 |
| Analysts Target Price | 12.2 | 96.5 |
| ValueRay Target Price | 8.3 | 34.3 |